Quick Answer
Iterum Therapeutics plc reported Long-Term Debt of $11.45 million for fiscal year 2023.
Iterum Therapeutics plc Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2023 | $11.45M | +13.5% |
| 2022 | $10.09M | +45.7% |
| 2021 | $6.93M | -69.1% |
| 2020 | $22.46M | +194.6% |
| 2019 | $7.62M | -41.7% |
| 2018 | $13.08M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $12.46M | +34.0% | +6.8% |
| June 30, 2023 | $11.67M | +37.2% | +7.3% |
| March 31, 2023 | $10.88M | +41.0% | +7.8% |
| December 31, 2022 | $10.09M | +45.7% | +8.6% |
| September 30, 2022 | $9.30M | +51.6% | +9.4% |
| June 30, 2022 | $8.50M | +59.2% | +10.2% |
| March 31, 2022 | $7.71M | +26.6% | +11.3% |
| December 31, 2021 | $6.93M | -69.1% | +13.0% |
- Iterum Therapeutics plc showed an increase of +13.5% in Long-Term Debt compared to the prior fiscal year.
- Over the 2018–2023 period, Iterum Therapeutics plc’s long-term debt has declined by 12.4% (from $13.08 million to $11.45 million).
- The most recent figure is from Iterum Therapeutics plc’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 28, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: